Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.41 |
| ▸ | TUBB | P07437 | 1/20 | 0.41 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.41 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.41 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.41 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.41 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.41 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.41 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.41 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3071474 | 0.85 | LMNA (0.41) | ALDH1A1NPC1LMNAHTTSMN1; SMN2 | |
| SCHEMBL7815176 | 0.75 | ADRA1A (0.53) | ALDH1A1GAACYP1A2CYP2C19LMNA | |
| SCHEMBL4443109 | 0.75 | CYP3A4 (0.56) | ALDH1A1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL6504793 | 0.74 | ACP3 (0.61) | ALDH1A1GAACYP3A4NPC1HSD17B10 | |
| SCHEMBL485336 | 0.73 | HSP90AA1 (0.45) | CYP1A2CYP3A4CYP2C9CYP2C19NPC1 | |
| SCHEMBL9391336 | 0.71 | CES2 (0.50) | NPC1KMT2ARAB9ASMN1; SMN2CA12 | |
| SCHEMBL7044804 | 0.71 | LDHA (0.55) | ALDH1A1CYP1A2NPC1RAB9ACA1 | |
| SCHEMBL6494407 | 0.71 | APP (0.52) | GAACYP2C19NPC1LMNAHTT | |
| SCHEMBL6504941 | 0.71 | MAPT (0.44) | ALDH1A1LMNAHTTTAS1R3TAS1R1 | |
| SCHEMBL3064489 | 0.70 | CYP3A4 (0.61) | ALDH1A1GAACYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1743881-B1 | Phenyl-benzyl-ketones | RUANE MICHAEL (AU) | 2010-12-22 | — | — | EP | disclosed |
| US-20100273891-A1 | ISOFLAVONE METABOLITES | Ruane, Michael (AU) | 2010-10-28 | — | — | US | disclosed |
| US-7799955-B2 | Isoflavone metabolites | Ruane, Michael (AU) | 2010-09-21 | — | — | US | disclosed |
| US-20090209655-A1 | ISOFLAVONE METABOLITES | G. J. CONSULTANTS PTY. LTD. (AU) | 2009-08-20 | — | — | US | disclosed |
| US-20080125481-A1 | ISOFLAVONE METABOLITES | JOANNOU GEORGE EUSTACE | 2008-05-29 | — | — | US | disclosed |
| EP-1743881-A1 | Phenyl-benzyl-ketones | G.J. Consultants Pty Ltd (AU) | 2007-01-17 | — | — | EP | disclosed |
| EP-1189897-B1 | ISOFLAVONE METABOLITES | G J CONSULTANTS PTY LTD (AU) | 2006-10-18 | — | — | EP | disclosed |
| US-7056952-B1 | for example, 3'-hydroxy-dihydrodaidzein, 5-hydroxy-O-demethylangolesin; for treating hormone dependent conditions and other diseases and disorders; anticarcinogenic agents | G.J. CONSULTANTS PTY. LTD. (AU) | 2006-06-06 | — | — | US | disclosed |
| US-20050222248-A1 | Isoflavone metabolites | JOANNOU GEORGE E | 2005-10-06 | — | — | US | disclosed |
| EP-1189897-A1 | ISOFLAVONE METABOLITES | G.J. Consultants Pty Ltd (AU) | 2002-03-27 | — | — | EP | disclosed |
| WO-2000066576-A1 | ISOFLAVONE METABOLITES | G.J. CONSULTANTS PTY LTD (AU) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222248-A1 | Isoflavone metabolites | CYP19A1, ESR1, CYP21A2 | ALDH1A1 1244/4885GAA 4172/4885CYP1A2 30/4885 |
| US-20100273891-A1 | ISOFLAVONE METABOLITES | CYP19A1, ESR1, CYP21A2 | ALDH1A1 1124/4885GAA 4123/4885CYP1A2 37/4885 |
| US-20090209655-A1 | ISOFLAVONE METABOLITES | CYP19A1, ESR1, CYP21A2 | ALDH1A1 1124/4885GAA 4123/4885CYP1A2 37/4885 |
| US-20080125481-A1 | ISOFLAVONE METABOLITES | CYP19A1, ESR1, CYP21A2 | ALDH1A1 1124/4885GAA 4123/4885CYP1A2 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.